Valneva Posts €174.7M In Preliminary 2025 Revenues, Up From €169.6M In 2024, With €109.7M Cash; Guides 2026 Total Revenues Of €155M-€170M, Product Sales €145M-€160M, With Phase 3 Lyme Disease Data Expected In H1 2026
Benzinga Newsdesk 8 months ago
NewsGuidance
Total Revenues of €174.7 million in line with guidance, including €157.9 million in product salesStrong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt
- Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales
- Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing
- 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the year
- Chief Executive Officer's contract renewed for a further three-year term, ensuring continuity in leadership